Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer

Hata,Shinro; Nomura,Takeo; Iwasaki,Kazunori; Sato,Ryuta; Yamasaki,Mutsushi; Sato,Fuminori; Mimata,Hiromitsu

doi:10.3892/or.2017.5669

Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer

Authors:
- Shinro Hata
- Takeo Nomura
- Kazunori Iwasaki
- Ryuta Sato
- Mutsushi Yamasaki
- Fuminori Sato
- Hiromitsu Mimata
View Affiliations

Affiliations: Department of Urology, Oita University Faculty of Medicine, Yufu, Oita 879-5593, Japan
Published online on: May 24, 2017 https://doi.org/10.3892/or.2017.5669
Pages: 120-128

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional protein, playing roles in glucose and lipid metabolism, inflammation, angiogenesis, and tumorigenesis. Recent research suggests that ANGPTL4 is induced by hypoxia and is a useful diagnostic or prognostic marker for various cancers. However, it remains unclear whether ANGPTL4 expression influences prostate cancer. Here we examined the biological and clinical relevance of ANGPTL4 expression in prostate cancer. Firstly we examined ANGPTL4 expression in the prostate cancer cell lines LNCaP and LNCaP/CH incubated at 1% O2 for at least 6 months. We compared cellular proliferation, migration, and ANGPTL4 secretion in a culture medium between these cell lines. In addition, we investigated the effect of various concentrations of recombinant ANGPTL4 protein (rANGPTL4) on cellular proliferation and intracellular signaling pathways. Moreover, we used ANGPTL4 knockdown by RNA interference to investigate the influence of ANGPTL4 expression on these cell lines. Finally, we investigated the correlation between ANGPTL4 expression in prostate cancer specimens and clinicopathological parameters using immunohistochemistry. Our data suggested that the expression of ANGPTL4 in hypoxic conditions was 14.4-fold higher than that in normoxic condition. ANGPTL4 secretion in the culture medium increased 7.0-fold. In addition, rANGPTL4 increased cellular proliferation 1.72-fold via Akt activation. Moreover, ANGPTL4 knockdown decreased cell growth and its secretion by 25.7 and 41.4%, respectively, compared with the control. A multivariate analysis showed that positive ANGPTL4 expression in the resected specimens was an independent prognostic indicator of biochemical recurrence (P=0.03, hazard ratio = 2.02). Our results show that ANGPTL4 is induced by hypoxia and promotes cancer progression via the activated PI3K/Akt pathway. Moreover, ANGPTL4 can be used as a prognostic marker for prostate cancer patients undergoing radical prostatectomy.

View Figures

View References

1	Stewart BW and Wild CP: World Cancer Report 2014. International Agency for Research on Cancer World Health Organization; 2014
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Scardino PT, Linehan W Marston, Zelefsky MJ and Vogelzang NJ: Comprehensive Textbook of Genitourinary Oncology (4th). Lippincott Williams and Wilkins. Philadelphia, PA: 2011.
4	Höckel M and Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
5	Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
6	Yamasaki M, Nomura T, Sato F and Mimata H: Chronic hypoxia induces androgen-independent and invasive behavior in LNCaP human prostate cancer cells. Urol Oncol. 31:1124–1131. 2013. View Article : Google Scholar : PubMed/NCBI
7	Tan MJ, Teo Z, Sng MK, Zhu P and Tan NS: Emerging roles of angiopoietin-like 4 in human cancer. Mol Cancer Res. 10:677–688. 2012. View Article : Google Scholar : PubMed/NCBI
8	Zhu P, Goh YY, Chin HF, Kersten S and Tan NS: Angio-poietin-like 4: A decade of research. Biosci Rep. 32:211–219. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kersten S, Lichtenstein L, Steenbergen E, Mudde K, Hendriks HF, Hesselink MK, Schrauwen P and Müller M: Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler Thromb Vasc Biol. 29:969–974. 2009. View Article : Google Scholar : PubMed/NCBI
10	Mandard S, Zandbergen F, van Straten E, Wahli W, Kuipers F, Müller M and Kersten S: The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J Biol Chem. 281:934–944. 2006. View Article : Google Scholar : PubMed/NCBI
11	Lu B, Moser A, Shigenaga JK, Grunfeld C and Feingold KR: The acute phase response stimulates the expression of angiopoietin like protein 4. Biochem Biophys Res Commun. 391:1737–1741. 2010. View Article : Google Scholar : PubMed/NCBI
12	Kubo H, Kitajima Y, Kai K, Nakamura J, Miyake S, Yanagihara K, Morito K, Tanaka T, Shida M and Noshiro H: Regulation and clinical significance of the hypoxia-induced expression of ANGPTL4 in gastric cancer. Oncol Lett. 11:1026–1034. 2016.PubMed/NCBI
13	Zhu P, Tan MJ, Huang RL, Tan CK, Chong HC, Pal M, Lam CR, Boukamp P, Pan JY, Tan SH, et al: Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(−):H2O2 ratio and confers anoikis resistance to tumors. Cancer Cell. 19:401–415. 2011. View Article : Google Scholar : PubMed/NCBI
14	Ifon ET, Pang AL, Johnson W, Cashman K, Zimmerman S, Muralidhar S, Chan WY, Casey J and Rosenthal LJ: U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3. Cancer Cell Int. 5:19–31. 2005. View Article : Google Scholar : PubMed/NCBI
15	Sato R, Yamasaki M, Hirai K, Matsubara T, Nomura T, Sato F and Mimata H: Angiopoietin-like protein 2 induces androgen-independent and malignant behavior in human prostate cancer cells. Oncol Rep. 33:58–66. 2015.PubMed/NCBI
16	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kim SH, Park YY, Kim SW, Lee JS, Wang D and DuBois RN: ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res. 71:7010–7020. 2011. View Article : Google Scholar : PubMed/NCBI
18	Rohwer N and Cramer T: Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 14:191–201. 2011. View Article : Google Scholar : PubMed/NCBI
19	Karakashev SV and Reginato MJ: Progress toward overcoming hypoxia-induced resistance to solid tumor therapy. Cancer Manag Res. 7:253–264. 2015.PubMed/NCBI
20	Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B, Winnard PT Jr, et al: HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene. 31:1757–1770. 2012. View Article : Google Scholar : PubMed/NCBI
21	Li H, Ge C, Zhao F, Yan M, Hu C, Jia D, Tian H, Zhu M, Chen T, Jiang G, et al: Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology. 54:910–919. 2011. View Article : Google Scholar : PubMed/NCBI
22	Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW and Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 167:528–534. 2002. View Article : Google Scholar : PubMed/NCBI
23	Roehl KA, Han M, Ramos CG, Antenor JA and Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol. 172:910–914. 2004. View Article : Google Scholar : PubMed/NCBI
24	Ng KT, Xu A, Cheng Q, Guo DY, Lim ZX, Sun CK, Fung JH, Poon RT, Fan ST, Lo CM, et al: Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma. Mol Cancer. 13:196–212. 2014. View Article : Google Scholar : PubMed/NCBI
25	Nakayama T, Hirakawa H, Shibata K, Nazneen A, Abe K, Nagayasu T and Taguchi T: Expression of angiopoietin-like 4 (ANGPTL4) in human colorectal cancer: ANGPTL4 promotes venous invasion and distant metastasis. Oncol Rep. 25:929–935. 2011. View Article : Google Scholar : PubMed/NCBI
26	Shibata K, Nakayama T, Hirakawa H, Hidaka S and Nagayasu T: Clinicopathological significance of angiopoietin-like protein 4 expression in oesophageal squamous cell carcinoma. J Clin Pathol. 63:1054–1058. 2010. View Article : Google Scholar : PubMed/NCBI
27	Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR and Massagué J: TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 133:66–77. 2008. View Article : Google Scholar : PubMed/NCBI
28	Kim I, Kim HG, Kim H, Kim HH, Park SK, Uhm CS, Lee ZH and Koh GY: Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J. 346:603–610. 2000. View Article : Google Scholar : PubMed/NCBI
29	Yang YH, Wang Y, Lam KS, Yau MH, Cheng KK, Zhang J, Zhu W, Wu D and Xu A: Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4. Arterioscler Thromb Vasc Biol. 28:835–840. 2008. View Article : Google Scholar : PubMed/NCBI